Wellington Management Group’s Ascendis Pharma A/S ASND Stock Holding History

Wellington Management Group’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$413M	Sell	1,548,636 -208,997	-12%	-$48.8M	0.07%	250
2026 Q1	$402M	Sell	1,757,633 -5,088	-0.3%	-$1.14M	0.08%	235
2025 Q4	$376M	Sell	1,762,721 -36,210	-2%	-$7.48M	0.07%	251
2025 Q3	$358M	Buy	1,798,931 +880,836	+96%	+$164M	0.06%	268
2025 Q2	$158M	Buy	918,095 +330,332	+56%	+$53.8M	0.03%	413
2025 Q1	$91.6M	Sell	587,763 -116,412	-17%	-$16.6M	0.02%	526
2024 Q4	$96.9M	Sell	704,175 -557,305	-44%	-$73.3M	0.02%	537
2024 Q3	$188M	Sell	1,261,480 -1,351,376	-52%	-$182M	0.03%	408
2024 Q2	$356M	Sell	2,612,856 -133,016	-5%	-$18.1M	0.06%	259
2024 Q1	$415M	Sell	2,745,872 -502,421	-15%	-$71.7M	0.07%	252
2023 Q4	$409M	Sell	3,248,293 -28,879	-0.9%	-$2.88M	0.08%	246
2023 Q3	$307M	Buy	3,277,172 +128,272	+4%	+$12M	0.06%	283
2023 Q2	$281M	Buy	3,148,900 +215,108	+7%	+$18.7M	0.05%	321
2023 Q1	$315M	Sell	2,933,792 -119,813	-4%	-$13.7M	0.06%	287
2022 Q4	$373M	Sell	3,053,605 -618,621	-17%	-$71.8M	0.07%	252
2022 Q3	$379M	Buy	3,672,226 +123,089	+3%	+$11.7M	0.08%	235
2022 Q2	$330M	Sell	3,549,137 -1,116,442	-24%	-$105M	0.07%	261
2022 Q1	$548M	Buy	4,665,579 +594,855	+15%	+$68.9M	0.09%	210
2021 Q4	$548M	Buy	4,070,724 +125,480	+3%	+$18.7M	0.09%	221
2021 Q3	$629M	Buy	3,945,244 +510,971	+15%	+$69.9M	0.11%	191
2021 Q2	$452M	Sell	3,434,273 -58,060	-2%	-$7.74M	0.08%	249
2021 Q1	$450M	Buy	3,492,333 +90,775	+3%	+$13.8M	0.08%	241
2020 Q4	$567M	Buy	3,401,558 +149,797	+5%	+$24.8M	0.1%	198
2020 Q3	$502M	Buy	3,251,761 +1,465,470	+82%	+$211M	0.1%	183
2020 Q2	$264M	Buy	1,786,291 +116,145	+7%	+$15.9M	0.06%	282
2020 Q1	$188M	Sell	1,670,146 -47,189	-3%	-$6.13M	0.05%	314
2019 Q4	$239M	Buy	1,717,335 +923,269	+116%	+$103M	0.05%	353
2019 Q3	$76.5M	Buy	794,066 +674,527	+564%	+$75.2M	0.02%	606
2019 Q2	$13.8M	Buy	119,539 +9,962	+9%	+$1.19M	﹤0.01%	1111
2019 Q1	$12.9M	Buy	109,577 +60,879	+125%	+$5.33M	﹤0.01%	1137
2018 Q4	$3.05M	Buy	48,698 +5,467	+13%	+$344K	﹤0.01%	1521
2018 Q3	$3.06M	Sell	43,231 -16,090	-27%	-$1.11M	﹤0.01%	1596
2018 Q2	$3.95M	Buy	59,321 +41,786	+238%	+$2.75M	﹤0.01%	1559
2018 Q1	$1.15M	Buy	+17,535	New	+$986K	﹤0.01%	1872

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Wellington Management Group's ASND Position: Q2 2026 in Review

Wellington Management Group reduced its Ascendis Pharma A/S (ASND) stake by 12% in Q2 2026, selling an estimated $48.8M and leaving 1,548,636 shares worth $413M. The position accounts for 0.07% of the portfolio, ranked #250.

Wellington Management Group first reported a position in ASND in Q1 2018 and has held it in 34 quarters since. The position peaked at $629M in Q3 2021. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Wellington Management Group held 1,548,636 shares of Ascendis Pharma A/S worth $413M as of Q2 2026.
Wellington Management Group sold 208,997 Ascendis Pharma A/S shares in Q2 2026, an estimated $48.8M.
Ascendis Pharma A/S made up 0.07% of Wellington Management Group's portfolio in Q2 2026, its #250 holding.
Wellington Management Group first reported a position in Ascendis Pharma A/S in Q1 2018 and has held it in 34 quarters since.
Wellington Management Group's Ascendis Pharma A/S position peaked at $629M in Q3 2021.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.